| |
*ER/PR+/HER2- n (%)
|
ER/PR+/HER2+ n (%)
|
ER−/PR−/HER2 + HER2 enriched n (%)
|
ER−/PR−/HER2-Triple Negative n (%)
|
|---|
| |
132 (62.6%)
|
19 (9.0%)
|
15 (7.1%)
|
45 (21.3%)
|
|
Histologic grade
|
|
Grade 1
|
33 (25.0)
|
5 (26.3)
|
1 (6.7)
|
2 (4.4)
|
|
Grade 2
|
59 (44.7)
|
10 (52.6)
|
8 (53.3)
|
23 (51.1)
|
|
Grade 3
|
21 (15.9)
|
3 (15.8)
|
3 (20.0)
|
13 (28.8)
|
|
Not specified/missing
|
19 (14.4)
|
1 (5.3)
|
3 (20.0)
|
7 (15.5)
|
|
Age
|
|
< 50 years
|
50 (37.8)
|
10 (52.6)
|
5 (33.3)
|
21 (46.7)
|
|
≥ 50 years
|
64 (48.5)
|
6 (31.6)
|
7 (46.7)
|
19 (42.2)
|
|
Age not specified/missing
|
18 (13.6)
|
3 (15.8)
|
3 (20.0)
|
5 (11.1)
|
|
Stage
|
|
Stage I and Stage II
|
5 (29.4)
|
0 (0.0)
|
0 (0.0)
|
2 (28.6)
|
|
Stage III
|
12 (70.6)
|
1 (100.0)
|
3 (100.0)
|
5 (71.4)
|
- *ER/PR+/HER2-: ER+ or PR+ or both, and HER2-
- ER/PR+/HER2+: ER or PR+ or both, and HER2+
- ER−/PR−/HER2+: ER – and PR- and HER2+
- ER−/PR−/HER2-: ER- ad PR- and HER2-
